site stats

Cisplatin ic50 a549

WebNov 29, 2024 · This study revealed that cisplatin resistant A549 lung cancer cells can be identified by their increased levels of mitochondrial mass. However, Mito-High cells … WebImmunofluorescence results elucidated that cellular ROS level in Cisplatin-induced A549 cells increases in a dose-dependent manner. Both immunofluorescence and flow cytometry results revealed that the apoptotic rate of A549 cells increases with the elevation of Cisplatin dose.

Molecules Free Full-Text The Challenging Treatment of …

WebNov 19, 2013 · A549 cells were exposed to cisplatin (CDDP) at an IC50 dose (12 µM) or a range of carboplatin (CBCDA) doses and total intracellular ROS levels were measured … WebMar 22, 2024 · The IC50 (drug concentration producing 50% growth inhibition) was calculated with GraphPad Prism Version 5.0 Software. Cell proliferation assay Cell … dutchman log repair https://iaclean.com

Enhanced expression of lncRNA ZXF1 promotes cisplatin …

WebJan 3, 2003 · We used the IC50 concentrations for both Gleevec and cisplatin to treat A549 cells in culture, and assessed the viability of the cells by MTT assays at the different time points (Figure 4 ). Gleevec (2 μM) and cisplatin (64 μM) both inhibited the growth of the tumor cells individually after treatment of the cells for 48 hour. WebIC 50 values for cisplatin, curcuminoid, and combination treatments in A549 cell culture. Standard deviation values are provided after the ± symbol for each inhibitory concentration value. Cell... WebNov 19, 2013 · A549 and DU145 cells were exposed to cisplatin at an IC50 dose (12 μM and 20 μM, respectively) and ROS levels were measured at the indicated time points by incubating with H 2 DCFDA or MitoSox fluorescent probes. ROS levels in treated vs. non treated cells at each time point were analyzed independently for each probe by two-way … in a nutshell lss is considered

National Center for Biotechnology Information

Category:Cells exhibit increased fold changes in IC50 concentrat Open-i

Tags:Cisplatin ic50 a549

Cisplatin ic50 a549

Enhanced expression of lncRNA ZXF1 promotes cisplatin …

WebNational Center for Biotechnology Information WebMar 17, 2024 · To establish the cisplatin-resistant cell line, A549-R, A549 cells were treated with a stepwise increasing concentration of cisplatin (Sigma-Aldrich, USA) as previously described. 29, 30 The CAFs and normal fibroblasts (NFs) were isolated from NSCLC tissues and adjacent normal tissues by primary culture, as previously described, respectively. …

Cisplatin ic50 a549

Did you know?

WebJan 3, 2003 · We have also shown that A549 cells are resistant to cisplatin treatment (IC50 64 microM). Addition of Gleevec to the A549 cells treated with cisplatin resulted in a synergistic cell killing effect, suggesting that Gleevec can potentiate the … WebFeb 4, 2024 · The IC50 concentration of cisplatin was required to achieve 50% of maximal growth inhibition after 72 h of exposure, and their standard errors were 0.82 ± 0.07 μM for A549 and 0.85 ± 0.06 μM...

WebDDP with IC50 of 133.3 and 63.7 μM was obtained for A549/DDP cells with siNC or siUSP14#1 ... USA; CRM‐CCL‐185), A549 cisplatin‐resistant (A549/DDP; National Infrastructure of Cell Line Resource, Beijing, China; 1101HUM‐PUMC000519), and human lung bronchial epithelial 16HBE cells (Shanghai Fuheng Biotechnology Co., Ltd. China; … WebThe cisplatin sensitivity of A549/DDP by the MTT assay, IC50 = 2.2μg/mL. The cisplatin sensitivity of A549 by the MTT assay, IC50 = 0.8μg/mL (B) Wound healing assays were performed to reveal the relative mobility. The line graphs show the mean ± SD of three scratches from one representative experiment.

WebThe cisplatin sensitivity of A549/DDP by the MTT assay, IC50 = 2.2μg/mL. The cisplatin sensitivity of A549 by the MTT assay, IC50 = 0.8μg/mL (B) Wound healing assays were … WebDec 29, 2009 · Fig. 3B confirms that, unlike cisplatin, a conventional chemotherapeutic agent, mitaplatin selectively induced cell death in human cancer A549 cells, but not in normal MRC-5 cells under the similar treatment conditions. To address whether the selective killing of cancer cells by mitaplatin might be a consequence of its selective uptake, we ...

WebIC 50 s of oxaliplatin in HCT116 and A549 cancer cells in the absence and presence of WLR treatment Source publication +2 Aqueous extract of Lithospermi radix attenuates oxaliplatin-induced...

WebIn A549 cells, the IC 50 concentration of cisplatin- resistant cells was determined to be 43.01 µM compared to 6.14 µM in the original parental cell line; a 7-fold increase in the concentration... in a nutshell miniaturesWebApr 11, 2024 · A549 and H358 cells were seeded in 6-well plates for 24 h prior to transfection with siRNA targeting BATF3, IRF5, ZBTB38, and corresponding non-targeting controls. A total of 150 nM of siRNA was added to each experiment made up of the target siRNA and topped up with the appropriate concentration of non-targeted controls where … dutchman tileWebJul 23, 2015 · The IC50 of cisplatin for A549 and SPC-A1 cells under hypoxia was 3.38-fold and 1.57-fold higher as compared to that under normoxia respectively as showing by the … in a nutshell ncisWebJul 17, 2024 · Importantly, we show that treatment of cancer cells with concentrations of cisplatin that result in 50% effect (i.e., IC50) in multiwell plate assays trigger the emergence of growth arrested cells that exhibit highly enlarged morphology, remain viable and adherent to the culture dish, and metabolize the tetrazolium salt 3-(4,5-dimethylthiazol-2 ... dutchman popup campers 2020WebDec 1, 2024 · microRNA IC50 inhibit concentration by 50% Keywords Colorectal neoplasiaa Drug resistance Oxaliplatin ABCB1 GSTP1 miRNA 1. Introduction Colorectal cancer is one of the major fatal malignancies, which is the third and second most prevalent cancer in males and females respectively. dutchman study guidein a nutshell law book seriesWebWith the treatment prolongation of 4 μmol/L Cisplatin in A549 cells, Bcl-2 and caspase-3 were downregulated, while BAD upregulated. Conclusions: Cisplatin treatment induces … in a nutshell nyt